Coronary Artery Disease (CAD) screening is largely based on stress ECG testing that has a limited diagnostic accuracy, especially in women. Additionally, there are growing concerns over exposure to radiation and cutbacks on payment for costly cardiac imaging.
HyperQ stress ECG testing provides a low-cost, noninvasive, radiation-free and highly reliable first line CAD diagnostic solution for private cardiology practices as well as cardiology departments in hospitals. HyperQ is based on solid scientific and clinical research and is FDA-cleared and CE-marked.
- Higher sensitivity in diagnosing ischaemia
- Fewer false alarms in non-ischaemic patients
- Performs equally well in women and men
- Provides clear results in patients with equivocal standard stress ECG test results